<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-61797</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Consensus Document on the Evaluation and Treatment of Moderate-to-Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology</dc:title>
<dc:description xml:lang="en">The treatment of psoriasis has been revolutionized by the introduction of biologic agents; these agents achieve skin clearance and long-term improvement without the risk of toxicity that has limited use of the classic systemic treatments. The role of systemic treatment in the management of psoriasis is being reviewed on the basis of a large volume of scientific evidence on the efficacy and safety of biologic agents, and new therapeutic goals and strategies are being devised for patients with moderate-to-severe psoriasis. This has led to the need to establish severity criteria that will provide the rationale for the indication of the different systemic agents currently available for the treatment of moderate-to-severe psoriasis, as well as therapeutic goals, efficacy measures, therapeutic strategies, screening protocols, and choice of treatment based on the risk-benefit ratio of the different agents. These criteria must be established through consensus by experienced dermatologists and based on available scientific evidence. The present document reflects the consensus of the Spanish Psoriasis Group on these different issues in the management of moderate-to-severe psoriasis (AU)</dc:description>
<dc:creator>López-Estebaranz, JL</dc:creator>
<dc:creator>Vanaclocha, F</dc:creator>
<dc:creator>Daudén, E</dc:creator>
<dc:creator>Ferrándiz, C</dc:creator>
<dc:creator>Puig, L</dc:creator>
<dc:creator>Carrascosa, JM</dc:creator>
<dc:creator>Moreno, JC</dc:creator>
<dc:creator>Vázquez-Veiga, H</dc:creator>
<dc:creator>Hernanz, JM</dc:creator>
<dc:creator>Sánchez-Carazo, JL</dc:creator>
<dc:creator>Bordas, X</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tratamiento de la psoriasis se ha visto revolucionado por la introducción de los agentes biológicos, que permiten obtener blanqueamientos y mejorías a largo plazo sin el riesgo de toxicidad que ha venido limitando el tratamiento de estos pacientes con agentes sistémicos clásicos. Se ha acumulado abundante evidencia científica con respecto a la eficacia y seguridad de los agentes biológicos, que ha llevado a revisar el papel del tratamiento sistémico en general y ha permitido establecer nuevos objetivos y estrategias terapéuticas en los pacientes con psoriasis moderada a grave. En este contexto nuevo se hace necesario establecer, de forma consensuada por especialistas expertos y basada en la evidencia científica disponible, criterios de gravedad que justifiquen la indicación de los diferentes tratamientos sistémicos actualmente disponibles para la psoriasis, así como objetivos terapéuticos y parámetros de eficacia, estrategias de tratamiento, cribaje de los pacientes y selección del tratamiento basada en criterios de beneficio/riesgo. El presente documento recoge el consenso del Grupo Español de Psoriasis en estos diferentes aspectos del manejo de la psoriasis moderada a grave (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;100(4): 277-286, mayo 2009. tab</dc:source>
<dc:identifier>ibc-61797</dc:identifier>
<dc:title xml:lang="es">Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis* de la Academia Española de Dermatología y Venereología</dc:title>
<dc:subject>^d25123^s22045</dc:subject>
<dc:subject>^d29627</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22016</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12002^s22067</dc:subject>
<dc:subject>^d13339^s22041</dc:subject>
<dc:subject>^d13339^s37748</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d30940^s22012</dc:subject>
<dc:subject>^d13339^s22048</dc:subject>
<dc:subject>^d13339^s22049</dc:subject>
<dc:subject>^d11207^s22045</dc:subject>
<dc:subject>^d10987^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>200905</dc:date>
</metadata>
</record>
</ibecs-document>
